Brought to you by 
Laekna in-licenses two more oncology pipeline assets from Novartis
19 May 2022
Executive Summary
Shanghai biotech Laekna Therapeutics Shanghai Co. Ltd. licensed exclusive worldwide rights to oral pan-AKT kinase inhibitors UPB795 (uprosertib) and ASB183 (afuresertib) from Novartis Pharma AG.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Laekna in-licenses two more oncology pipeline assets from Novartis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice